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1. INTRODUCTION
Helmint infections which are influenced by parasites, affect 
more than one billion people in the world. Owing to the 
narrow spectrum of antihelmintic drugs it is needed to use 
combination chemotheraphy to control mixed infections 
(1). Combinations of oxfendazole-oxyclozanide (2) and 
fenbendazole-praziquantel-pyrantel pamoate (3) are the 
most common treatments of helmint infections. Another 
drug combination, which is the theme of our work, consists 
of oxantel pamoate, pyrantel pamoate and praziquantel and 
notably is being used to treat dogs (4). Although these three 
active ingredients are highly used in veterinary medicine, 
praziquantel and pyrantel pamoate exist in drug 
formulations for human.
To date, many HPLC methods have been developed to analyze 
praziquantel in various biological matrices (3, 5-9). HPLC 
analysis of pyrantel (10) alone or in combination with oxantel 
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In the present study, simple, rapid and precise HPLC methods 
were developed which would be useful for quality control of 
pharmaceutical dosage forms containing praziquantel (PRZ), 
pyrantel pamoate (PPA) and oxantel pamoate (OPA). The first 
method (M1) was developed for the analysis of PRZ; separation 
was achieved using a reversed–phase column (4.6 x 150 mm, 
5 µm) C18, a mobile phase comprising ACN:MeOH:20 mM 
phosphate buffer (0.2 % TEA, pH 4.5) (50:10:40, v/v/v) and 
UV detection at 210 nm. PPA and OPA were analysed 
simultaneously using a separate method (M2) by employing 
the same column and flow rate. In accordance with the second 
method (M2), detection wavelength was set at 295 nm and a 
mobile phase of ACN:MeOH:20 mM phosphate buffer (0.2 % 
TEA, pH 4.5) (12:3:85, v/v/v) was used. Benazepril 
hydrochloride (BZP) and paracetamol (PAR) were used as 
internal standards (IS) of the methods M1 and M2, respectively. 
Both methods were validated based on the parameters such as 
specifity, linearity, precision, accuracy, limit of detection 
(LOD) and limit of quantitation (LOQ) besides system 
suitability tests. Forced degradation studies were performed to 
indicate specifity of the proposed methods. The methods were 
found linear over the concentration ranges of 0.5–7.5 µg/mL, 
1–15 µg/mL and 2–40 µg/mL for PRZ, PPA and OPA, 
respectively. Correlation coefficients (r) of the regression 
equations were greater than 0.999 in all cases. The precision of 
the methods was demonstrated using intra- and inter-day assay 
RSD values which were less than 1% in all instances. Accuracy 
of the proposed methods was tested on placebo tablets spiked 
with known amounts of actives. Resulting recoveries of assays 
were in the range of 99.9–101.1 % whereas, those from 
commercial tablets were 99.4–100.8 %. 
Keywords: Oxantel pamoate, Pyrantel pamoate, Praziquantel, 
HPLC, analytical method validation.
Tatar et al.
A validated HPLC method for oxantel, pyrantel and praziquantel28 Marmara Pharm J 19: 27-35, 2015
(11) and febantel-praziquantel (12) have also been reported.
Gonzalez et al. (5) determined praziquantel by using C18 
column at 217 nm after solid phase extraction for preparing 
the sample. Enantiomers of praziquantel in human plasma 
were separated by Liu and Stewart by using cellulose-based 
chiral column and UV detector (6). Lerch and Blashcke (13) 
worked on praziquantel’s metabolism in rat liver microsomes 
by the help of CE and LC-MS and revealed that R-(-) 
e n a n t i o m e r  m e t a b o l i z e s  t o  t r a n s -  a n d  c i s - 4 -
hydroxypraziquantel. As continuance, Meier and Blaschke 
(14) determined praziquantel’s mono-, di-, trihydroxy 
metabolites and their glucuronide and sulphate conjugates in 
human urine by using CE-MS and LC-MS. The same 
r e s e a r c h  g r o u p  i d e n t i f i e d  t r a n s -  a n d  c i s - 4 -
hydroxypraziquantel and an undefined monohydroxy 
metabolite in isolated rat hepatocytes by using gradient 
elution method (8). Schepmann and Blaschke (7), identified 
the new monohydroxy metabolite mentioned above, through 
combined MSn and NMR techniques including a reversed 
phase HPLC column and ACN:H2O (28:72 v/v) mobil phase, 
as 8-hydroxypraziquantel. Bonato et al. (15), reported the 
analysis of praziquantel and trans-4-hydroxypraziquantel in 
swine plasma samples by using a LC-MS-MS method which 
is comprised of a cyanopropyl column and MeOH:H2O (3:7, 
v/v) plus 0.5% of acetic acid mobile phase.
A method for determination of praziquantel in human 
plasma was developed by the utilization of C18 reversed 
phase column and ACN:MeOH:H2O (36:10:54 v/v/v) as 
mobile phase (9). Other report on HPLC determination of 
praziquantel in human plasma reveals the use of diazepam 
as internal standard using a similar reversed-phase column 
and ACN:H2O (70:30, v/v), after liquid-liquid extraction of 
plasma samples (16). An enantioselective analysis method 
for praziquantel, (+)-(S)-praziquantel and (−)-(R)-4-
hydroxypraziquantel enantiomers in human plasma by 
chiral LC-MS2 method was reported. The method was 
reported to employ a Chiralpak AD column and 
hexane:isopropanol (75:25, v/v) mobile phase (17).
Praziquantel in bulk powder and its pharmacopoeial 
impurities were determined by using a calixarene column 
and mobile phase consisting of ACN and 25 mM ammonium 
acetate (18). The recent work describing determination of 
praziquantel in bulk and in synthetic mixtures through a 
reversed-phase high-performance liquid chromatography 
method was published in 2014 (19). Li et al. (20) reported 
HPLC and NMR – based analysis of praziquantel tablets to 
compare products from different manufacturers and to 
determine batch-to-batch variation from a single manufacture.
Through another work; praziquantel, fenbendazole and 
pyrantel pamoate combination was tried to be determined in 
dog plasma but not succeed by the reason of highly polar 
and basic character of pyrantel. Consequently, pyrantel was 
determined seperately due to its early retention time (3). 
For the determination of pyrantel pamoate in binary mixture 
with mebendazole C8 reversed phase column and phosphate 
buffer:ACN:TEA mobil phase were used at 290 nm (21). 
Determination of pyrantel tartarate in medicated feeds has 
been confirmed as a stable method of recent date (22). For 
the evaluation of pyrantel pamoate in binary mixture with 
oxantel pamoate, ACN with butylamine modifier mobile 
phase and C8 reversed phase column were used (11). 
Oxfendazole-oxyclozanide (2) binary mixture and combined 
preparations of similar antihelmintic drugs as mebendazole, 
fenbendazole, albendazole and their related impurities were 
determined together (23). 
Nonetheless the absence of a report on determination of 
pyrantel pamoate, oxantel pamoate and praziquantel 
mixture from biological fluids or pharmaceutical dosage 
forms simultaneously, directs us to emphasize determination 
of these drugs. A specific, accurate, and precise method that 
could be applied to the quantitative analysis of tablets and 
other pharmaceutical preparations containing these three 
active ingredients was developed and validated for the 
determination of raw material and pharmaceutical product 
and for quality control, content uniformity and dissolution 
tests.
2. EXPERIMENTAL
2.1. Materials and reagents
Pyrantel pamoate (PPA), oxantel pamoate (OPA), 
praziquantel (PRZ) standarts and pharmaceutical dosage 
forms ( table ts)  conta ining these  APIs  (Act ive 
Pharmaceutical Ingredients), were kindly provided by 
Topkim Topkapı Medicine Premix (İstanbul, Turkey). 
Benazepril HCl and paracetamol standarts were gifts from 
Novartis Pharmaceuticals (İstanbul, Turkey) and Drogsan 
(İstanbul, Turkey) respectively. Methanol and acetonitrile 
were of gradient grade and purchased from Merck company 
(Darmstadt, Germany). Triethylamine (TEA) and 
orthophosphoric acid (85%) were of analytical grade and 
procured from Fluka and Carlo-Erba Companies 
respectively. Potassium dihydrogen phosphate procured 
from Riedel-de Häen. Sodium hydroxide, hydrochloric acid 
and hydrogen peroxide were purchased from Merck 
company (Darmstadt, Germany).  
2.2. Instrumentation
The liquid chromatographic system used in the present 
study consisted of an Agilent Technologies 1100 series 
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instrument equipped with a quaternary solvent delivery 
system and a model Agilent series G-13158 photodiode 
array detector. A Rheodyne syringe loading sample injector 
with a 50 µl sample loop was used for the injections of 
analytes. Chromatographic data were collected and 
processed using HP-Vectra VL-DOO DT software. The 
separation was performed at ambient temperature on a 
reversed phase Waters Symmetry C18 Column (150 mm x 
4.6 mm; 5µm particle size). A Waters Symmetry C18 
analytical guard column packed with the same sorbent was 
used.
SMILES were generated from the structures using the ACD/
ChemSketch version 8.0 molecular editor (http://www.
acdlabs.com) and then log P and pKa values were calculated 
using ALOGPS 2.102 logP/logS calculation software (24, 
25). Validity of the Log P values were also checked using 
another online software, Molinspiration online property 
calculation toolkit (26). The calculated log P and pKa values 
for all the compounds are given in Table 1.
2.3. Mobile phases
Two kinds of mobile phase systems were used in our work :
M1 : ACN:MeOH:20 mM phosphate buffer (0.2 % TEA, pH 
4.5) (50:10:40, v/v/v)
M2 : ACN:MeOH:20 mM phosphate buffer (0.2 % TEA, pH 
4.5) (12:3:85, v/v/v)
Preparation of phosphate buffer : 2.722 g KH2PO4 was 
dissolved in sufficient bidistilled water and 2 ml TEA was 
added to produce 1000 ml. The final pH of the solution was 
adjusted to the 4.5 with orthophosphoric acid.
2.4. Standard stock solutions
Stock solutions of OPA, PPA, PRZ, PAR and BZP : 20 mg 
of each was weighed and dissolved in methanol to produce 
100 ml by ultrasonication for 10 minutes. The volumetric 
flasks were wrapped with foil paper to keep out of light and 
preserved at +4°C.
2.5. Standard stock solutions for precision studies
The precision of the proposed method was assessed as 
repeatability performing five replicate injections of three 
different sample solutions with concentations 0.6-2.0-6.0 
µg/ml for PRZ, 12.5 µg/ml for PPA and 3.0-15.0-37.5 µg/
ml for OPA
2.6. Sample preparations 
Ten tablets were weighed, their mean weight were 
determined as 1050.03 mg and then they were finely 
powdered. 38.25 mg of powder was transferred into a 100 
Table 1. Structures and calculated physico-chemical properties of the APIs.
Structures and chemical names of the APIs Formula & M.W. 
(g.mol-1)











































2.26 2.25 11.00 a
8.00 b
1 Log P and pKa values were calculated using ALOGPs software (http://vcclab.org/lab/alogps/start.html).
2 Log P values were calculated using Molinspiration software (http://www.molinspiration.com/).
a basic pKa ; 
b acidic pKa. All Log P and pKa values of  Pyrantel and Oxantel were calculated from their bases.
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ml volumetric flask and diluted to 100 ml with methanol, 
sonicated for 20 min and 10 ml sample taken from this 
solution was centrifuged at 3000 rpm for 15 min. To a 1 ml 
aliquot from supernatant was added 100 µl of benazepril 
HCl stock solution and 750 µl of paracetamol stock solution 
the made up the volume of 10 ml with mobile phase.
2.7. Chromatographic conditions
Two methods used for chromatographic analysis of the 
APIs can be described as follows.
M1 : A reversed-phase Waters Symmetry C18 column with 
a particle size of 5µm and dimentions of 4.6 x 150 mm 
were used. The mobile phase consisted ACN:MeOH:20 
mM phosphate buffer (0.2% TEA, pH 4.5) (50:10:40, v/v/v) 
and delivered at a flow rate of 1.5 ml/min. Injection volume 
was 50 µl. The analytes were monitored using a PDA 
detector at 210 nm (bandwidth: 4 nm). The buffer contained 
20 mM KH2PO4 and 0.2% TEA; and the final pH were 
adjusted to pH 4.5 with H3PO4.
M2 : A reversed-phase Waters Symmetry C18 column with 
a particle size of 5 µm and dimentions of 4.6 x 150 mm 
were used. The mobile phase consisted of ACN:MeOH:20 
mM phosphate buffer (0.2 % TEA, pH 4.5) (12:3:85, v/v/v) 
and delivered at a flow rate of 1.5 ml/min. Injection volume 
was 50 µl. The analytes were monitored using a PDA 
detector at 295 nm (bandwidth: 4 nm). 
3. RESULT and DISCUSSION
3.1. Determination of the mobile phase
The pharmaceutical dosage form which is the theme of our 
work consists of 50 mg of praziquantel (PRZ), 140 mg of 
pyrantel pamoate (PPA) and 545 mg of oxantel pamoate 
(OPA) for each tablet. These three active ingredients are 
being governed in veterinary medicine together with human 
use. We planned this work on the basis of absence of an 
analytical method for the determination of pharmaceutical 
dosage forms containing PRZ, PPA and OPA combinations 
by HPLC. For accessing the optimum chromatographic 
conditions lots of attemps were held. The first attempt was 
trying to use water included mobile phases. By using mobile 
phase systems which consist of ACN:MeOH:water at 
different levels, PRZ’s peaks were evaluated at acceptable 
retention time but because of the basic characters of PPA 
and OPA high tailing factor, unacceptable retention profile 
and peaks holding trogether with the void volume occured. 
For later-dated experiences, buffer solutions of KH2PO4 and 
orthophosphoric acid (for pH adjustment) were  prepared. 
When the pH of the buffer solution was acidic the wide 
peak shapes of pyrantel and oxantel got narrower but 
acceptable elution and retention time were not assessed. 
Changing pH did not affect non-basic PRZ; peak shape and 
retention time of it didn’t vary. When PPA and OPA were 
well-resolved from each other there was no eluting potential 
for PRZ and very late eluting potential for pamoic acid that 
could interfere the following injections. As PRZ had an 
acceptable retention time, PPA and OPA were not well-
resolved from each other and from the void volume 
therefore an ion-pair forming agent, sodium hexane 
sulfonate (PIC B-6), was used. During this trial, either no 
well-resolving profile for PPA and OPA or late retention 
time for PRZ were carried out. Consequently gradient 
elution method was tried to determinate the multi-
component tablet. By the help of gradient elution PRZ, PPA 
and OPA were eluted with success but some disadvantages 
of the system were confirmed. If we considered the ratio of 
active ingredients of tablet there would be no sufficient 
resolving profile for PPA and OPA. It was necessary to 
detect PRZ at 210 nm but shift and noise were occured at 
this wavelenght. Time of one analysis lasted at least 30 
mins. Tailing of pamoic acid peak could interefere with 
PRZ. After all these attempts a method to analyse the four 
component of the tablet can not be optimized so two 
different methods were enhanced for PPA and OPA together 
and PRZ alone. In 1998, Morovján et al. (3) determined 
praziquantel, fenbendazole and pyrantel pamoate in dog 
plasma by facing the same problems so that they determined 
pyrantel pamoate alone and praziquantel–fenbendazole 
together.  By using 20 mM KH 2PO4 buffer  and 
orthophosphoric acid for pH adjustment to 4.5, the best 
results were obtained. TEA was added to the mobile phase 
for getting reproducibility and avoiding secondary 
interaction between silanol groups and PPA, OPA as the 
cause of unacceptable peak shapes (27). Since PRZ has 
been nonbasic it was not affected by this change. After 
testing the combinations of ACN-MeOH-20 mM KH2PO4 
(0.2% TEA, pH 4.5) with ratios 10:50:40, 30:30:40, 
40:20:40 and 50:10:40 v/v/v it was approved to work with 
the fourth one to determine PRZ. This method was rapid, it 
lasted nearly 5 mins and pyrantel, oxantel and pamoic acid 
were eluted at void volume so no interference with PRZ and 
other injections. Flow rate was 1.5 ml/min and wavelength 
for detection was 210 nm for this method (M1). For 
acceptable retention times appertaining PPA and OPA, ratio 
of organic solvent was reduced in M1 system and a new 
system (M2) of ACN:MeOH:20 mM KH2PO4 (0.2% TEA, 
pH 4.5) 12:3:85 v/v/v was developed. Flow rate remained 
the same at M2 system but wavelength for detection was set 
to 295 nm to avoid noise and to achieve higher absorption 
of PPA and OPA. Required time for one analysis by 
employing M2 system was shorter than 6 mins and there 
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were no peak accounting for neither PRZ nor pamoic acid. 
Internal standarts; BZP for M1 system and PAR for M2 
system were used to eliminate errors of manual injection.
3.2. Validation of the analytical method
The aim of validation of an analytical method is to state 
whether it serves the aim or not (28). A developed method 
should pass the tests: precision, accuracy, limit of detection, 
limit of quantitation, specificity, linearity and range, 
ruggedness, robustness. Specificity symbolizes the 
selectivity of the system and means that a peak represents 
only one substance and no co-elution with the other 
ingredients of tablet, internal standards, impurities and 
degradation products. In our work, PRZ, PPA and OPA 
were discriminated from each other and internal standards 
on the basis of qualitative and quantitative aspect with 
acceptable resolution values (Please see Figure 1). By the 
help of recovery process it was confirmed that inactive 
ingredients of tablet did not affect the analysis. 
Since reference standards for impurities of active ingredients 
have not been supplied accelerated degradation studies were 
performed to provide an evidence for the specificity of the 
proposed method. Degradation experiments were designed 
using acid, base, oxidative agents, heat, UV and direct 
daylight and it was shown that degradation products’ peaks 
were quantitatively well-resolved from the peaks of active 
ingredients. Peak homogeneity of the compounds was 
checked using an Agilent 1100 Diode array detector (DAD) 
and it was demonstrated that a peak represents an active 
ingredient. Losses due to degradation experiments that drew 
Figure 1.  Typical chromatograms obtained from standard solutions of 
OPA, PPA and PRZ (Sample concentrations: PRZ = 3 µg/mL; BZP = 2 µg/
mL; PPA = 5 µg/mL; OPA = 10 µg/mL; PAR = 15 µg/mL).
Figure 2. Calibration plots of OPA, PPA and PRZ.
Table 2. Characteristics of PSE and CET calibration plots.
PRZ PPA OPA
Linearity range (µg.mL–1) 0.5–7.5 1–15 2–40
Slope* 0.7055 0.2807 0.2537
Intercept*  – 0.0458 – 0.0354 – 0.0184
Standard error of the slope 0.00066 0.00056 0.00028
Standard error of the intercept 0.00134 0.00091 0.00056
Correlation coefficient (r) 0.9997 0.9999 0.9998
Limit of detection (µg.mL–1) 0.014 0.024 0.016
Limit of quantification (µg.mL–1) 0.043 0.072 0.050
* : Mean of five injections.
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attention were caused by heating PRZ with acid and PRZ, 
OPA with base. It was observed that, direct exposure to 
daylight and UV irradiation decompose pyrantel whereas 
other two APIs did not. At the end of other degradation 
reactions no notable degradation product were detected. 
In the wake of calibration experiments, concentration levels 
ranging from 0.5-7.5 µg/ml for PRZ, 1-15 µg/ml for PPA 
and 2-40 µg/ml for OPA were found in linear correlation 
with detector response. Correlation coefficients of 
regression equations were calculated as 0.9995 for PRZ, 
0.99998 for PPA, 0.9996 for OPA due to high linearity 
(Please see Figure 2 and Table 2). By using calibration 
curves and LOD=3.3.ϭ/S and LOQ=10.ϭ/S criterions limit 
of detection (LOD) for PRZ, PPA and OPA were calculated 
as 0.014 µg/ml, 0.024 µg/ml and 0.016 µg/ml the limit of 
quantitation (LOQ) for PRZ, PPA and OPA were calculated 
as 0.043 µg/ml, 0.072 µg/ml, 0.050 µg/ml respectively. 
The precision of the proposed method was assessed as 
repeatability and intermediate precision. Recovery from 
placebo tablets and designation of the effect of different 
analyst on quantitative determination of compounds were 
planned as another intermediate precision experiment. The 
required results are depicted in Table 3. 
According to the data given in Table 4, changes between 
the concentration ratios have no negative effect on 
repeatability. Proximity between the data required by 
prescribed method and the actual data can be defined as 
Table 3. Summary of intra-day (repeatability) and inter-day (intermediate 












0.6 0.60 100.4 0.25 0.60 99.3 0.80
PRZ 2.0 1.98 99.2 0.29 1.99 99.4 0.33
6.0 5.97 99.6 0.18 5.97 99.5 0.44
1.2 1.21 100.4 0.42 1.20 99.8 0.12
PPA 5.0 4.98 99.5 0.62 5.02 100.4 0.18
12.5 12.44 99.5 0.23 12.44 99.5 0.49
3.0 2.99 99.7 0.32 3.03 100.9 0.40
OPA 15.0 15.04 100.2 0.27 14.94 99.6 0.30
37.5 37.64 100.4 0.27 37.80 100.8 0.13
*: Mean of five injections.
Table 4. Resolution of PRZ, PPA and OPA in laboratory-made mixtures 
using the proposed method.
Added (µg/mL) Found (µg/mL) % Recovery
PRZ PPA OPA PRZ PPA OPA  PRZ PPA OPA
2 5 5 2.00 4.98 5.07 100.2 99.6 101.4
2 5 10 2.00 4.97 9.97 99.9 99.3 99.7
2 5 15 1.99 4.93 15.20 99.4 98.7 101.3
2 5 20 2.00 4.94 20.26 99.8 98.7 101.3
2 5 30 2.01 5.01 30.39 100.3 100.2 101.3
   mean 99.9 99.3 101.0
      % RSD 0.35 0.67 0.71
2 1.5 15 2.01 1.48 15.08 100.5 98.9 100.5
2 2 15 1.99 1.98 15.06 99.6 99.1 100.4
2 5 15 2.01 4.96 15.08 100.3 99.1 100.6
2 8 15 2.00 7.92 14.91 100.1 99.0 99.4
2 12 15 1.99 11.91 14.99 99.3 99.3 99.9
   mean 99.9 99.1 100.2
      % RSD 0.51 0.13 0.51
0.6 5 15 0.61 4.99 15.10 101.3 99.8 100.7
1 5 15 1.01 5.03 15.10 101.2 100.6 100.6
2 5 15 2.03 5.04 15.07 101.3 100.9 100.5
4 5 15 4.01 5.05 15.13 100.2 101.0 100.8
6 5 15 6.08 5.02 15.09 101.4 100.3 100.6
   mean 101.1 100.5 100.6
      % RSD 0.50 0.48 0.13
Table 5. Stathistical analysis of assay results and recovery experiments in 
the placebo tablets and commercial samples.
Analyst – I Analyst – II
PRZ PPA OPA PRZ PPA OPA
Label claim 
(mg) 50 140 545 50 140 545
Mean of amount 
found (mg)* 50.413 139.721 542.906 49.922 139.153 544.715
Confidence 
limits ± 0.330 ± 0.719 ± 3.278 ± 0.462 ± 0.534 ± 3.556
Recovery % 100.826 99.800 99.616 99.843 99.395 99.948
RSD % 0.624 0.491 0.576 0.882 0.242 0.622
t – test** 2.225 1.819 0.961 t theoretical = 3.17 
***
Placebo tablets 
– added amount 
(mg)
54.781 153.388 597.117 53.825 150.710 586.694
Mean of amount 
found (mg) 55.054 154.292 600.683 54.424 150.608 592.972
Confidence 
limits ± 0.212 ± 0.854 ± 1.525 ± 0.430 ± 1.235 ± 2.119
Recovery % 100.497 100.589 100.597 101.112 99.932 101.070
RSD % 0.367 0.527 0.242 0.753 0.782 0.341
t – test** 1.780 1.705 2.748 t theoretical = 3.17 
***
    * Mean values represent six determinations.
  ** t-tests were calculated using mean recoveries.
*** t theoretical value was taken from t-table for 99% confidence level and 
N=12.
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accuracy and this work was held on placebo tablets having 
similar concentration with the test concentration. Two 
analyst worked on this attempt and the results were 
evaluated with % recovery. Upon getting high recovery 
values with placebo tablets, the developed method was 
decided to be applied to pharmaceutical dosage forms. 
Mean values of assay results obtained from two different 
analysts were analyzed through t-test  if there’s a statistically 
significant difference. Results showed that t values for 
placebo tablets and pharmaceutical products are not more 
than 3.17 which is the theoretical value for N=12 at 99% 
confidence limit, indicating no significant difference 
between the mean contents of the APIs obtained by two 
different analysts. The data gained by recovery studies were 
summarized in Table 5 and Table 6. 
In accordance with USP 23, system suitability tests are an 
integral part of a liquid chromatographic method, and they 
were used to verify that the proposed method was able to 
produce good resolution between the peaks of interest with 
high reproducibility (29). The system suitability was 
determined by making six replicate injections from freshly 
prepared standard solutions and analyzing each solute for 
their peak area, theoretical plates (N), resolution (R) and 
tailing factors (T). System suitability requirements for OPA, 
PPA and PRZ were a R.S.D. of peak areas and retention times 
less than 1%, peak resolution (R) greater than 2.0 between 
two adjacent peaks for three analytes, theoretical plate 
numbers (N) at least 2000 for each peaks and USP tailing 
factors (T) less than 1.5. The results of system suitability test 
in comparison with the required limits can be shown in Table 
7. Calculated k′ values of PRZ, PPA and OPA are 1.629, 
3.269 and 2.381 respectively reveals well-resolution and no 
need to prolong the time of analysis. According to the results 
presented, the proposed method fulfils these requirements 
within the accepted limits (Please see Figure 3).
4. CONCLUSION
According to the results the proposed method was found to 
be specific, accurate, precise and fast. There is no need for 
ion-pairing agents and gradient elution and also no need for 
Figure 3. Typical chromatograms obtained from the analysis of tablet 
formulation comprises of  OPA, PPA and PRZ.
Table 6. Recovery of APIs after accelerated degradation experiments 
under several stress conditions.
Stress  
conditions* Time Recovery (%)
Relative retention 
times (RRT) of 
degradation 
products**
(h) PRZ OPA PPA PRZ OPA PPA
Fresh standard 




stored in dark at 
room 
temperature
24 99.573 98.98 99.306 0.846, 0.714 - 0.699
Exposed to direct 
sun light in 
MeOH at room 
temperature
24 98.808 98.864 42.949 0.844, 0.714 0.698 0.694
Exposed to UV 
irradiation in 
MeOH at room 
temperature UV 
(254 nm)




at 80 ºC 4 97.64 98.224 95.104
0.844, 
0.714 - 0.697
0.5 N HCl, 
heating at 80 ºC 4 89.334 98.231 94.439
0.330, 
0.437  - 0.700
0.714, 
0.846
0.5 N NaOH, 








%3 H202, heating 
at 80 ºC 2 95.358 98.28 97.178
0.714, 
0.846 - 0.696
Table 7. System suitability results of the developed method.
Method Compound k’ α R N T RSD
M1
BZP 0.716 - - 2462 1.370 0.32
PRZ 1.629 2.275 6.298 4848 1.238 0.43
M2
PAR 1.079 - - 2860 1.326 0.29
OPA 2.381 2.206 6.010 2380 1.242 0.21
PPA 3.269 1.373 3.068 3225 1.245 0.19
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liquid-liquid and solid phase extraction to prepare samples. 
The time of analysis lasts for 5 and 6 minutes for the 
systems M1 and M2, respectively. Considering the 
advantages of the method; it can be used for quality control, 
content uniformity and stability tests of PRZ, PPA and 
OPA.
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ÖZET
Bu çalışma kapsamında, prazikuantel (PRZ), pirantel pamoat 
(PPA) ve oksantel pamoat (OPA) içeren farmasötik dozaj 
şekillerinin kalite kontrolünde kullanılabilecek basit, hızlı ve 
duyarlı yüksek basınçlı sıvı kromatografisi (HPLC) yöntemleri 
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diğer yöntemde (M2) ise aynı kolonda ve akış hızında 
çalışılırken, detektör dalga boyu 295 nm olarak belirlenmiştir. 
M2 yönteminin hareketli fazının içeriği ACN – MeOH – 20 
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şeklinde belirlenmiştir. M1 yöntemiyle analizi yapılan PRZ 
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özgünlüğü gösterilmiştir. Yapılan doğrusallık çalışmalarında 
PRZ, PPA ve OPA için sırasıyla 0.5-7.5 µg/ml, 1-15 µg/ml ve 
2-40 µg/ml aralıklarında elde edilen regresyon eşitliklerinin 
korelasyon katsayıları 0.999’dan yüksek bulunmuş ve 
yöntemlerin doğrusallığı gösterilmiştir. Yöntemlerin 
kesinliğini gösteren gün içi ve günler arası tekrarlanabilirlik 
deneylerinde elde edilen bağıl standart sapma (BSS) değerleri 
daima % 1’den küçük bulunmuştur. Doğruluk deneylerinde; 
geliştirilen yöntemlerin plasebo tabletlere uygulanmasından 
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bulunmuştur. Bu değerlerin, bitmiş ürünlerde % 99.4–100.8 
aralığında değiştiği saptanmıştır.
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